NCT06326606View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 27, 2024

Primary Completion Date

July 8, 2024

Study Completion Date

July 8, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

Psilocybin

Capsule containing active ingredient, psilocybin

DRUG

Placebo

Capsule with no active ingredients

Trial Locations (1)

5000

CMAX Clinical Research Pty Ltd, Adelaide

Sponsors
All Listed Sponsors
lead

MycoMedica Life Sciences PBC

INDUSTRY

NCT06326606 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants | Biotech Hunter | Biotech Hunter